BioSpace News Archive

Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical data that further evaluate the therapeutic peptide-drug conjugate platform, have been accepted by the European Hematology Association (EHA). The abstracts are now published online. Melflufen

COVID-19 doesn’t just attack a patient’s lungs, it damages the kidneys, but most Americans are unaware.

According to a new market report published by Persistence Market Research “Global Market Study on E-Prescribing: North America to Witness Highest Growth by 2019,” the global E-Prescribing market was valued at USD 250.2 million in 2013 and is expected to grow at a CAGR of 23.5% from 2013 to 2019, to reach an estimated value of USD 887.8 million in 2019.

According to a new market report published by Persistence Market Research “Global Market Study on Gamma Knife: Asia to Witness Highest Growth by 2020,” the global Gamma Knife market is valued at USD 526,733.2 thousand in 2014 and is expected to grow at a CAGR of 3.6% from 2014 to 2020 to reach an estimated value of USD 651,241.9 thousand in 2020.

According to a new market report published by Persistence Market Research “Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022”, the global next-generation antibody therapeutics market is project to be valued at US$ 2,250.0 Mn by the end of 2015 and is expected to expand at a CAGR of 13.0% from 2015 to 2022, to account for US$ 6,761.1 Mn by 2022.

Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced financial results for the first quarter ended March 31, 2020 and provided a corporate update. First Qua

Optical filters designed for real-time qPCR applications / COVID-19 testing can be ordered online now.

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers – – MCLA-117 demonstrates limited clinical activity in Phase 1 trial – – Extensive panel of novel CD3 bispecific antibodies provides important insights and avenues to maximize T‑cell engager biology – UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company”, “we”, or “our”), a

OncoSec launches broader #TogetherAgainstCancer campaign and is proud to partner with melanoma advocacy partners throughout the month of May [14-May-2020] PENNINGTON, N.J. and SAN DIEGO , May 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today that its partnering w

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-altered cancers and avapritinib in systemic mastocytosis.